A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Clinical trial NCT02699606 · COMPLETED
Trial details
- NCT number
- NCT02699606
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-08
- Primary completion
- 2021-10-12
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.